Ambrx Biopharma Inc. (AMAM) Stock Analysis
DELISTED 2024
What happened to Ambrx Biopharma Inc. (AMAM) stock?
Ambrx Biopharma Inc. (AMAM) no longer trades on public markets. It was delisted in March 2024. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ambrx Biopharma Inc. (AMAM) trades at $28.00. Ambrx Biopharma Inc. is a clinical-stage biotechnology company focused on developing engineered precision biologics. The company leverages its proprietary technology platform to create innovative therapies targeting various cancers. Market cap: $1.77B, Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for AMAM: AMAM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AMAM against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
AMAM: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Ambrx Biopharma Inc. (AMAM) Healthcare & Pipeline Overview
Ambrx Biopharma Inc. is a clinical-stage biotechnology firm specializing in engineered precision biologics, with a focus on innovative cancer therapies utilizing its proprietary expanded genetic code technology platform, positioning itself as a key player in the oncology treatment landscape.
What Is the Investment Thesis for AMAM?
Ambrx Biopharma Inc. presents a compelling investment thesis driven by its innovative pipeline and strategic collaborations. The company’s lead candidate, ARX788, targets a significant market opportunity in HER2-positive cancers, which represents a multi-billion-dollar market. With ongoing Phase 2/3 trials, successful outcomes could lead to accelerated approval and commercialization, potentially generating substantial revenue streams. Additionally, the development of ARX517 and ARX305 positions Ambrx to capitalize on the growing demand for targeted cancer therapies. The company's gross margin of 100% reflects its potential profitability upon commercialization, although the current negative profit margin of -1053.7% indicates the need for continued investment in R&D. As the oncology market continues to expand, driven by advancements in precision medicine, Ambrx's unique technology platform and diverse pipeline enhance its growth prospects. However, investors should remain cognizant of the inherent risks associated with clinical trials and regulatory approvals.
Based on FMP financials and quantitative analysis
AMAM Key Highlights
Market Cap of $1.77B reflects strong investor interest in innovative biotech solutions.
- P/E ratio of -13.86 indicates current losses typical for clinical-stage companies investing heavily in R&D.
- Gross margin of 100% suggests high potential profitability upon successful product commercialization.
- Profit margin of -1053.7% highlights the intensive investment in clinical trials and product development.
- Beta of -2.36 indicates high volatility, characteristic of biotech firms reliant on clinical trial outcomes.
Who Are AMAM's Competitors?
AMAM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BIESF Biotest AG | $32.00 | +0.00% | $1.60B | 48 |
| BLU BELLUS Health Inc. | $14.74 | +0.03% | $1.87B | 48 |
| DICE DICE Therapeutics, Inc. | $47.55 | +0.06% | $2.27B | — |
| EQRX EQRx, Inc. | $2.34 | -2.09% | $1.14B | — |
| FUSN Fusion Pharmaceuticals Inc. | $21.55 | +0.14% | $1.83B | 57 |
| GLPG Galapagos NV | $27.98 | +1.71% | $1.84B | 70 |
| ETON Eton Pharmaceuticals, Inc. | $59.91 | -2.55% | $1.64B | 98 |
| INVA Innoviva, Inc. | $21.04 | -2.05% | $1.55B | 94 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AMAM's Key Strengths?
Innovative proprietary technology platform for biologics development.
- Strong pipeline of product candidates targeting significant oncology markets.
- Established collaborations with major pharmaceutical companies enhance R&D capabilities.
What Are AMAM's Weaknesses?
Current negative profit margins due to high R&D expenditures.
- Dependence on successful clinical trial outcomes for future revenue generation.
- Limited market presence compared to larger, established biotech firms.
What Could Drive AMAM Stock Higher?
AMAM catalyst: Results from ongoing Phase 2/3 clinical trials for ARX788 are expected in late 2026, which could significantly impact the company's market position.
- Development of ARX517 in Phase 1 trials is critical for establishing its efficacy in prostate cancer treatment.
- Collaborations with major pharmaceutical companies are enhancing R&D capabilities and accelerating product development timelines.
What Are the Key Risks for AMAM?
Negative return on equity (-50.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory approval risks associated with clinical trial outcomes for Ambrx's product candidates.
- High R&D costs may continue to impact profitability and cash flow.
- Competitive pressures from other biotechnology firms could affect market share and pricing strategies.
What Are the Growth Opportunities for AMAM?
- Growth opportunity 1: Ambrx's lead product candidate, ARX788, targets the HER2-positive breast cancer market, which is valued at approximately $20 billion. With ongoing Phase 2/3 trials, successful results could lead to market entry by 2027, capitalizing on the urgent need for effective therapies in this segment.
- Early-stage clinical trials are crucial for establishing its efficacy and safety, with potential market entry by 2028.
- Growth opportunity 3: Ambrx is also developing ARX305 for renal cell carcinoma, a market expected to grow to $10 billion by 2026. The successful completion of investigational studies could position Ambrx favorably within this expanding market segment.
- Growth opportunity 4: The immuno-oncology sector is rapidly evolving, with a market size forecasted to reach $110 billion by 2027. Ambrx's candidates like ARX822 and ARX102 are poised to leverage this growth, with preclinical developments underway that could lead to clinical trials in the near future.
- Growth opportunity 5: Strategic collaborations with industry leaders such as Bristol Myers Squibb and AbbVie provide Ambrx with enhanced research capabilities and market access. These partnerships are expected to accelerate product development timelines and broaden the company's therapeutic reach.
What Opportunities Does AMAM Have?
- Expanding oncology market presents significant growth potential for Ambrx's products.
- Potential for accelerated approvals based on positive clinical trial results.
- Increasing demand for targeted therapies in cancer treatment supports pipeline development.
What Threats Does AMAM Face?
- Intense competition from other biotech firms in the oncology space.
- Regulatory hurdles and uncertainties associated with clinical trial approvals.
- Market volatility impacting investor sentiment and funding availability.
What Are AMAM's Competitive Advantages?
- Proprietary expanded genetic code technology provides a unique competitive advantage.
- Strong pipeline of differentiated product candidates targeting high-value oncology markets.
- Established collaborations with leading pharmaceutical companies enhance credibility and resources.
What Does AMAM Do?
Founded in 2003 and headquartered in La Jolla, California, Ambrx Biopharma Inc. is a clinical-stage biologics company that specializes in the discovery and development of engineered precision biologics through its proprietary expanded genetic code technology platform. The company’s lead product candidate, ARX788, is an anti-HER2 antibody-drug conjugate (ADC) currently undergoing various clinical trials aimed at treating breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors. Notably, ARX788 is in ongoing Phase 2/3 clinical trials targeting HER2-positive metastatic breast cancer and gastric cancer, highlighting the company's commitment to addressing critical unmet medical needs in oncology. In addition to ARX788, Ambrx is advancing two earlier-stage product candidates: ARX517, an anti-PSMA ADC in Phase 1 clinical trials for prostate cancer, and ARX305, an anti-CD70 ADC that is in investigational new drug-enabling studies for renal cell carcinoma and other cancers. The company is also exploring multiple product candidates in the immuno-oncology space, such as ARX822, a fab-small molecule bispecific in preclinical development, and ARX102, an IL-2 pathway agonist aimed at enhancing the patient's immune response. Ambrx Biopharma has established collaborations with notable partners, including Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health, which bolster its research capabilities and market reach. The company is positioned to leverage its innovative technology to create a robust pipeline of biologics that address significant challenges in cancer treatment.
What Products and Services Does AMAM Offer?
- Develops engineered precision biologics using proprietary expanded genetic code technology.
- Focuses on creating antibody-drug conjugates (ADCs) targeting various cancers.
- Conducts clinical trials for lead product candidates, including ARX788, ARX517, and ARX305.
- Explores immuno-oncology applications with multiple product candidates in development.
- Collaborates with major pharmaceutical companies to enhance research and development efforts.
- Aims to address unmet medical needs in oncology through innovative therapies.
How Does AMAM Make Money?
- Generates revenue through partnerships and collaborations with pharmaceutical companies.
- Plans to commercialize successful product candidates upon regulatory approval.
- Invests heavily in research and development to advance its pipeline of biologics.
- Utilizes proprietary technology to differentiate its products in the competitive landscape.
What Industry Does AMAM Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in precision medicine and an increasing focus on targeted therapies. Ambrx Biopharma Inc. operates within this dynamic landscape, positioning itself as a key player with its proprietary technology platform and a robust pipeline of engineered biologics. The competitive landscape includes notable peers such as BIESF, BLU, DICE, EQRX, and FUSN, each vying for market share in the lucrative oncology segment.
Who Are AMAM's Key Customers?
- Pharmaceutical companies seeking innovative biologic therapies.
- Healthcare providers looking for advanced treatment options for oncology patients.
- Research institutions collaborating on clinical trials and development projects.
Company Profile
Ambrx Biopharma Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in La Jolla, US. The company is led by CEO Daniel J. O'Connor. AMAM has traded publicly since 2023.
Financial Health
Ambrx Biopharma Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 34.87 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for Ambrx Biopharma Inc. stands at -50.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -53.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.44 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.2%, the inverse of the P/E and a quick read on earnings relative to price.
AMAM Valuation & Market Position
With a $1.77B market cap, Ambrx Biopharma Inc. sits in the small-cap segment of the market.
AMAM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative proprietary technology platform for biologics development.
- Strong pipeline of product candidates targeting significant oncology markets.
- Established collaborations with major pharmaceutical companies enhance R&D capabilities.
- Upcoming: Results from ongoing Phase 2/3 clinical trials for ARX788 are expected in late 2026, which could significantly impact the company's market position.
Bear Case
- Current negative profit margins due to high R&D expenditures.
- Dependence on successful clinical trial outcomes for future revenue generation.
- Limited market presence compared to larger, established biotech firms.
- Potential: Regulatory approval risks associated with clinical trial outcomes for Ambrx's product candidates.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
AMAM Latest News
No recent news available for AMAM.
Leadership: Daniel J. O'Connor
CEO
Daniel J. O'Connor has extensive experience in the biotechnology sector, having held various leadership roles in both public and private companies. He holds a degree in biochemistry and has a strong background in drug development and commercialization strategies. Prior to joining Ambrx, he served as CEO of multiple biotech firms, where he successfully led initiatives to advance innovative therapies.
Track Record: Under Daniel's leadership, Ambrx has made significant strides in advancing its clinical pipeline and establishing strategic partnerships with industry leaders. His focus on innovation and collaboration has positioned the company for future growth and success in the competitive biotechnology landscape.
Common Questions About AMAM (Healthcare)
What happened to Ambrx Biopharma Inc. (AMAM) stock?
Ambrx Biopharma Inc. (AMAM) no longer trades on public markets. It was delisted in March 2024. The figures below are historical and are not a current quote.
Can I still buy AMAM shares?
No. AMAM stopped trading on public markets in March 2024, so the shares are not available through a broker. Anything you see quoted for AMAM elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before AMAM stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Ambrx Biopharma Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Ambrx Biopharma Inc. do?
Ambrx Biopharma Inc. is a clinical-stage biotechnology company that develops engineered precision biologics, primarily focusing on antibody-drug conjugates (ADCs) for cancer treatment. Its lead product candidate, ARX788, targets HER2-positive cancers, while the company also explores other therapeutic areas through its innovative technology platform.
What do analysts say about AMAM stock?
Analysts generally view Ambrx Biopharma Inc. as a high-risk, high-reward investment given its clinical-stage status and reliance on successful trial outcomes. Key valuation metrics, such as the P/E ratio of -13.86, reflect the company's current losses, while the potential market size for its lead products offers significant growth considerations.
What are the main risks for AMAM?
Ambrx Biopharma Inc. faces several risks, including the potential for regulatory hurdles that could delay or prevent product approvals. Additionally, the company's high R&D expenditures may impact profitability, and competitive pressures from established biotech firms could affect its market position and pricing strategies.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The analysis is based on current available data and may be subject to change as new information becomes available.